Blog Category: On-Demand

The Bottom Line: Updated Strategies for Early Detection and Prevention of Anal Cancer

Unlike many other cancers, rates of anal cancer and death due to anal cancer are rising in the United States.  The increasing incidence is primarily seen in high-risk populations including men who have sex with men (MSM) and people living …

A Focus on Family Physicians in the Care of Patients Living with HIV

New diagnoses of HIV continue at a rapid pace despite the availability of preventative options. This is particularly true among underserved populations, including racial and ethnic minorities, who often go undiagnosed or underdiagnosed due to disparities in access to care. …

Diving into New and Emerging Non-Factor Therapies for Hemophilia and Discussing Advancements in New Options and Monitoring with Patients

Recent advances in the treatment of hemophilia, a genetically X-linked bleeding disorder, include non-factor prophylactic therapies such as factor VIII mimetics, anti-tissue factor pathway inhibitors (anti-TFPIs) and small interfering RNA (siRNA) treatments. Health care professionals (HCPs) treating patients with hemophilia …

Non-Factor Therapies in Hemophilia: Advancing Monitoring Strategies and Patient-Centered Care

Recent advances in the treatment of hemophilia, a genetically X-linked bleeding disorder, include non-factor prophylactic therapies such as factor VIII mimetics, anti-tissue factor pathway inhibitors (anti-TFPIs) and small interfering RNA (siRNA) treatments. Health care professionals (HCPs) treating patients with hemophilia …

Innovations in Immunoglobulin A Nephropathy: Shaping the Future of Treatment

Immunoglobulin A nephropathy (IgAN) is a progressive glomerular disease and a leading cause of chronic kidney disease (CKD), with up to 40% of patients advancing to kidney failure within two decades. Despite guideline-recommended management emphasizing supportive care and RAAS inhibition, …

Reimagining Management of Generalized Myasthenia Gravis: A Focus on FcRn Antagonists

Generalized myasthenia gravis (gMG) is a chronic neuromuscular disorder that results from destruction of the neuromuscular junction by pathogenic autoantibodies, partially through the actions of the neonatal Fc receptor (FcRn). Traditional therapies only partially alleviate the heavy disease burden and …